Regeneron
Trade Regeneron 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
REGN Key Statistics
Stock Snapshot
As of today, Regeneron(REGN) shares are valued at $751.49. The company's market cap stands at 78.86B, with a P/E ratio of 17.96 and a dividend yield of 46.9%.
On 2025-12-02, Regeneron(REGN) stock opened at $774.43, reached a high of —, and a low of —.
The Regeneron(REGN)'s current trading volume is 0, compared to an average daily volume of 1.27M.
In the last year, Regeneron(REGN) shares hit a 52-week high of $800.99 and a 52-week low of $476.49.
In the last year, Regeneron(REGN) shares hit a 52-week high of $800.99 and a 52-week low of $476.49.
REGN News
Regeneron Pharmaceuticals (REGN) has caught investor attention recently, with its stock navigating some modest ups and downs this month. Returns over the past t...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Tessera Therapeutics, Inc., on Monday announced a global collaboration to develop and commercialize TSRA-196....
Below is Validea's guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow, REGN rates highest using our Value Inv...
Analyst ratings
70%
of 30 ratingsMore REGN News
Key Points Sales of Regeneron Pharmaceuticals' Eylea have declined over the past few quarters due to competition. However, the company launched a new formulat...
Regeneron Pharmaceuticals and Sanofi recently announced that the European Commission approved Dupixent (dupilumab) for the treatment of moderate-to-severe chron...